Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Rituximab therapy for hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis. Clin Case Rep 2018 02;6(2):442-443

Date

02/16/2018

Pubmed ID

29445495

Pubmed Central ID

PMC5799646

DOI

10.1002/ccr3.1371

Abstract

Membranoproliferative glomerulonephritis associated with mixed cryoglobulinemia is the most common form of kidney disease observed in relation to hepatitis C virus (HCV) infection. Rituximab, a monoclonal antibody against CD20, is an effective treatment for severe and/or refractory HCV-related vasculitis and may evade the need for dialysis as in our patient.

Author List

Koratala A, Zeng X

Author

Abhilash Koratala MD Associate Professor in the Medicine department at Medical College of Wisconsin